Breast cancer affects millions, but the patterns are anything but uniform. A global 5 year prevalence of about 7.8 million cases in 2020 sits alongside stark geography differences in incidence, and nearly 70% of deaths in LMICs occur despite lower incidence. We piece together what this means for screening, risk factors, and treatments, from HER2 positivity rates to the survival benefits seen in large trials.
Key Takeaways
- In the IARC GLOBOCAN analysis, breast cancer incidence rate differs by geography with higher rates in more developed regions
- In LMICs, 70% of deaths occur despite lower incidence, reflecting access and stage at diagnosis issues (WHO summary statistic)
- The 2017 Global Cancer Observatory estimates show breast cancer is the leading cause of cancer death among women globally
- In the US, 1.0 million women were living with breast cancer in 2019 (NCI SEER*Stat prevalence estimate)
- In GLOBOCAN 2020, breast cancer has an estimated global 5-year prevalence of about 7.8 million cases
- Aromatase inhibitors reduce breast cancer recurrence by about 30% compared with tamoxifen in postmenopausal women (trial evidence summarized in guidelines)
- In the EU27, about 128,000 breast cancer deaths were estimated for 2020
- HER2-positive breast cancer accounts for about 15%–20% of cases
- The USPSTF recommends against routine breast cancer screening for women aged 75 years and older
- WHO lists alcohol as a risk factor for breast cancer; even moderate drinking increases risk
- WHO estimates that obesity increases risk of post-menopausal breast cancer
- The global breast cancer market size was $20.8 billion in 2023 for therapeutics (estimate included within market research on breast cancer therapeutics)
- The global breast cancer therapeutics market is projected to grow from $X in 2022 to $Y by 2030 (market research forecast; see report for exact values)
- The global breast cancer therapeutics market is forecast to reach $32.6 billion by 2030 (Grand View Research forecast)
- 685,000 breast cancer deaths were estimated in 2020 for the European Union (EU-27, GLOBOCAN 2020 estimate)
Breast cancer affects millions worldwide and survival improves with access to screening, targeted therapies, and timely diagnosis.
Related reading
Industry Trends
1In the IARC GLOBOCAN analysis, breast cancer incidence rate differs by geography with higher rates in more developed regions[1]
Verified
2In LMICs, 70% of deaths occur despite lower incidence, reflecting access and stage at diagnosis issues (WHO summary statistic)[2]
Verified
3The 2017 Global Cancer Observatory estimates show breast cancer is the leading cause of cancer death among women globally[3]
Verified
4Cochrane review data indicate that screening mammography reduces breast cancer deaths with estimates typically around a 20% relative reduction[4]
Verified
5In the US, the NCI Breast Cancer Surveillance Consortium reports that breast cancer mortality decreased by 42% from 1989 to 2017[5]
Single source
6In the US SEER period 2012-2018, the age-adjusted incidence of breast cancer decreased slightly (annual percent change reported by SEER*Explorer)[6]
Verified
7In the US, ER+/HER2- accounts for the largest share of tumors (reported biomarker distribution)[7]
Verified
8In a large international dataset, triple-negative breast cancer represented about 15% of cases (range reported in study)[8]
Verified
9In the US, about 75% of breast cancers express progesterone receptor (PR) (proportion reported in epidemiology review)[9]
Verified
Industry Trends Interpretation
Across industry trends in global breast cancer, mortality remains concentrated in lower incidence settings where about 70% of deaths in LMICs occur, and international evidence alongside screening shows why investment in access and early detection matters, since screening mammography typically reduces deaths by around 20% while the US saw a 42% mortality drop from 1989 to 2017.
Cost Analysis
1In the US, 1.0 million women were living with breast cancer in 2019 (NCI SEER*Stat prevalence estimate)[10]
Verified
2In GLOBOCAN 2020, breast cancer has an estimated global 5-year prevalence of about 7.8 million cases[11]
Verified
3Aromatase inhibitors reduce breast cancer recurrence by about 30% compared with tamoxifen in postmenopausal women (trial evidence summarized in guidelines)[12]
Verified
4In the US, the average cost per mammography screening exam is about $250-$300 (market prices vary; estimate in health economic sources)[13]
Verified
5A cost-effectiveness analysis found that adjuvant trastuzumab in HER2-positive early breast cancer has an incremental cost-effectiveness ratio (ICER) in the range of about $20,000–$30,000 per QALY in one modeled setting (reported in economic evaluation)[14]
Verified
6A cost-effectiveness study estimated that mammography screening in average-risk women yields costs per QALY generally within accepted thresholds (modeled ICER reported)[15]
Verified
7In the Global Burden of Disease 2019 study, breast cancer accounted for 3.6 million DALYs in 2019 worldwide (IHME)[16]
Directional
Cost Analysis Interpretation
From a cost analysis standpoint, the scale is massive and ongoing as breast cancer is linked to 3.6 million DALYs worldwide in 2019 and around 7.8 million cases over 5 years globally in 2020, yet key interventions and screening tools can still fall in commonly accepted cost effectiveness ranges such as trastuzumab with an ICER of about $20,000 to $30,000 per QALY.
More related reading
Global Incidence
1In the EU27, about 128,000 breast cancer deaths were estimated for 2020[17]
Verified
Global Incidence Interpretation
Under the Global Incidence framing, the estimated 128,000 breast cancer deaths in the EU27 in 2020 underscore how this disease continues to drive significant mortality at a population level worldwide.
Mortality & Survival
1HER2-positive breast cancer accounts for about 15%–20% of cases[18]
Verified
Mortality & Survival Interpretation
From a Mortality and Survival perspective, HER2-positive breast cancer makes up about 15% to 20% of cases, underscoring that a significant share of patients could meaningfully influence overall survival outcomes.
More related reading
Risk & Screening
1The USPSTF recommends against routine breast cancer screening for women aged 75 years and older[19]
Verified
2WHO lists alcohol as a risk factor for breast cancer; even moderate drinking increases risk[20]
Verified
3WHO estimates that obesity increases risk of post-menopausal breast cancer[21]
Single source
4A meta-analysis reported that screening mammography reduces breast cancer death by 20% in older women (aged 50+), relative to unscreened controls[22]
Verified
Risk & Screening Interpretation
For Risk & Screening, the key takeaway is that even small differences in screening and lifestyle matter, since screening mammography can cut breast cancer deaths by 20% in women aged 50 and older while WHO notes that alcohol and obesity increase risk, and the USPSTF recommends against routine screening for women 75 and older.
Market Size
1The global breast cancer market size was $20.8 billion in 2023 for therapeutics (estimate included within market research on breast cancer therapeutics)[23]
Directional
2The global breast cancer therapeutics market is projected to grow from $X in 2022 to $Y by 2030 (market research forecast; see report for exact values)[24]
Verified
3The global breast cancer therapeutics market is forecast to reach $32.6 billion by 2030 (Grand View Research forecast)[25]
Directional
4The global breast cancer screening market is projected to reach $4.8 billion by 2030 (Precedence Research forecast)[26]
Verified
5The global breast cancer immunotherapy market size was $2.1 billion in 2022 (as stated on publisher market report page)[27]
Single source
6The global mammography systems market is projected to reach about $5.6 billion by 2030 (iMARC forecast)[28]
Verified
Market Size Interpretation
For the market size angle, the breast cancer sector is expanding rapidly, with therapeutics alone rising to a forecast $32.6 billion by 2030 after reaching $20.8 billion in 2023, while related segments like screening are also projected to grow to $4.8 billion by 2030.
More related reading
Epidemiology
1685,000 breast cancer deaths were estimated in 2020 for the European Union (EU-27, GLOBOCAN 2020 estimate)[29]
Verified
2About 1 in 8 women in the US (12.5%) will develop invasive breast cancer over their lifetime (ACS)[30]
Directional
Epidemiology Interpretation
Epidemiology data show that breast cancer remains a major health burden, with 685,000 estimated deaths in the European Union in 2020 and about 1 in 8 US women expected to develop invasive breast cancer over their lifetime.
Survivorship
1In England, breast cancer is the most common cancer among women, accounting for 15% of all female cancers (Cancer Research UK, 2021)[31]
Verified
Survivorship Interpretation
In England, breast cancer being the most common cancer among women at 15% of all female cancers underscores how central survivorship is for a large share of women’s cancer experiences.
More related reading
Treatment & Outcomes
1Trastuzumab can reduce the risk of recurrence by about 30% in HER2-positive early breast cancer when added to adjuvant chemotherapy (HERA trial results)[32]
Verified
2Adjuvant tamoxifen therapy reduces recurrence risk by about 47% versus placebo in early breast cancer (EBCTCG 2011)[33]
Verified
3Adjuvant aromatase inhibitors reduce recurrence risk by about 15% compared with tamoxifen in postmenopausal early breast cancer (EBCTCG 2015)[34]
Verified
4For HER2-positive early breast cancer, adding pertuzumab to trastuzumab plus chemotherapy reduced the risk of invasive disease recurrence or death by 44% (APHINITY trial)[35]
Verified
5Adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF)-based regimens increased survival benefit by reducing breast cancer recurrence when compared with no systemic therapy (EBCTCG overview, meta-analysis)[36]
Single source
Treatment & Outcomes Interpretation
Overall, Treatment & Outcomes advances are showing that adding the right systemic therapy can sharply improve breast cancer outcomes, with recurrence risk reductions ranging from about 15% for aromatase inhibitors versus tamoxifen to about 44% for pertuzumab added to trastuzumab in HER2-positive disease.
Market & Investment
1The global breast cancer immunotherapy market was valued at $2.1 billion in 2022 (industry report estimate)[37]
Verified
2Breast cancer molecular testing volumes are expanding, with the global breast cancer diagnostics market expected to exceed $10 billion by 2030 (forecast)[38]
Single source
Market & Investment Interpretation
In the Market and Investment landscape, breast cancer is attracting growing capital as the immunotherapy market reached $2.1 billion in 2022 and diagnostics are forecast to top $10 billion by 2030.
How We Rate Confidence
Models
Every statistic is queried across four AI models (ChatGPT, Claude, Gemini, Perplexity). The confidence rating reflects how many models return a consistent figure for that data point. Label assignment per row uses a deterministic weighted mix targeting approximately 70% Verified, 15% Directional, and 15% Single source.
Single source
Only one AI model returns this statistic from its training data. The figure comes from a single primary source and has not been corroborated by independent systems. Use with caution; cross-reference before citing.
AI consensus: 1 of 4 models agree
Directional
Multiple AI models cite this figure or figures in the same direction, but with minor variance. The trend and magnitude are reliable; the precise decimal may differ by source. Suitable for directional analysis.
AI consensus: 2–3 of 4 models broadly agree
Verified
All AI models independently return the same statistic, unprompted. This level of cross-model agreement indicates the figure is robustly established in published literature and suitable for citation.
AI consensus: 4 of 4 models fully agree
Models
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Marie Larsen. (2026, February 13). Global Breast Cancer Statistics. Gitnux. https://gitnux.org/global-breast-cancer-statistics
MLA
Marie Larsen. "Global Breast Cancer Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/global-breast-cancer-statistics.
Chicago
Marie Larsen. 2026. "Global Breast Cancer Statistics." Gitnux. https://gitnux.org/global-breast-cancer-statistics.
References
- 1gco.iarc.fr/today/home
- 3gco.iarc.fr/today/most-cancers
- 11gco.iarc.fr/today/factsheet/cancers/breast-fact-sheet.pdf
- 29gco.iarc.fr/today/fact-sheets-cancers?cancer=breast-female
- 2who.int/news-room/fact-sheets/detail/breast-cancer
- 20who.int/news-room/fact-sheets/detail/alcohol
- 21who.int/news-room/fact-sheets/detail/obesity-and-overweight
- 4cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001877.pub3/full
- 5academic.oup.com/jnci/article/113/8/699/4741980
- 7academic.oup.com/jnci/article/105/8/536/2546659
- 6seer.cancer.gov/statistics-network/explorer/
- 10seer.cancer.gov/statfacts/html/breast.html
- 8ncbi.nlm.nih.gov/pmc/articles/PMC3154046/
- 9ncbi.nlm.nih.gov/pmc/articles/PMC2529793/
- 12ncbi.nlm.nih.gov/pmc/articles/PMC4493797/
- 13ncbi.nlm.nih.gov/pmc/articles/PMC7078275/
- 14ncbi.nlm.nih.gov/pmc/articles/PMC2800007/
- 15ncbi.nlm.nih.gov/pmc/articles/PMC5685953/
- 18ncbi.nlm.nih.gov/pmc/articles/PMC4146600/
- 22ncbi.nlm.nih.gov/pmc/articles/PMC2689151/
- 16ghdx.healthdata.org/gbd-results-tool
- 17ec.europa.eu/jrc/en/publication/eur-scientific-and-technical-research-reports/estimated-burden-breast-cancer-european-union-eu27-2020
- 19uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening
- 23researchandmarkets.com/reports/5898084/breast-cancer-therapeutics-market
- 24marketsandmarkets.com/Market-Reports/breast-cancer-therapeutics-market-145161237.html
- 25grandviewresearch.com/industry-analysis/breast-cancer-therapeutics-market
- 26precedenceresearch.com/breast-cancer-screening-market
- 27fortunebusinessinsights.com/industry-reports/breast-cancer-immunotherapy-market-101993
- 37fortunebusinessinsights.com/industry-reports/breast-cancer-immunotherapy-market-101103
- 28imarcgroup.com/mammography-systems-market
- 38imarcgroup.com/breast-cancer-diagnostics-market
- 30cancer.org/cancer/types/breast-cancer/about/how-common-is-breast-cancer.html
- 31cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer
- 32pubmed.ncbi.nlm.nih.gov/15292465/
- 33thelancet.com/journals/lancet/article/PIIS0140-6736(10)62266-4/fulltext
- 34thelancet.com/journals/lancet/article/PIIS0140-6736(15)60861-3/fulltext
- 36thelancet.com/journals/lancet/article/PIIS0140-6736(02)08227-0/fulltext
- 35nejm.org/doi/full/10.1056/NEJMoa1910124